Effect of somatostatin on TSH levels in non-toxic sporadic goiter

J. Varea, M. Paredes, G. Garces, C. Ochoa, C. Avila, M. J. Coloma, R. Briones, A. M. Comaru-Schally, A. V. Schally

Research output: Contribution to journalArticlepeer-review


Somatostatin (SS-14; growth hormone-release inhibiting hormone) was infused into eight patients with non-toxic sporadic goiter and into eleven normal control subjects. Each patient was given 150 μg of somatostatin as an intravenous bolus and 350 μg by infusion over a period of 60 minutes. Somatostatin did not lower the basal TSH levels as compared to the pre-infusion levels in this type of goiter, but produced a decrease in the TSH response to TRH during and after the infusion.

Original languageEnglish (US)
Pages (from-to)627-631
Number of pages5
JournalHormone and Metabolic Research
Issue number12
StatePublished - 1990
Externally publishedYes


  • goiter
  • somatostatin
  • TRH
  • TSH

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Effect of somatostatin on TSH levels in non-toxic sporadic goiter'. Together they form a unique fingerprint.

Cite this